SCHEMBL10211237

SCHEMBL10211237

COC(=O)c1cc2nc(Cl)c(-c3ccccc3)nc2cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.48
PKM P14618 2/20 0.48
ALDH1A1 P00352 4/20 0.43
HPGD P15428 3/20 0.42
HSD17B10 Q99714 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
NPC1 O15118 1/20 0.42
TSHR P16473 1/20 0.42
RAB9A P51151 1/20 0.42
GABRA1 P14867 2/20 0.41
GABRG2 P18507 2/20 0.41
GABRB3 P28472 2/20 0.41
GABRA5 P31644 2/20 0.41
GABRA3 P34903 2/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
PDE5A O76074 1/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9960774 0.80 ALDH1A1 (0.57) KDM4EPKMALDH1A1HPGDNPC1
SCHEMBL1459040 0.80 ALDH1A1 (0.57) KDM4EPKMALDH1A1HPGDNPC1
SCHEMBL10212181 0.77 CSNK2A1 (0.44) KDM4EPKMALDH1A1TSHRGABRA1
SCHEMBL10211229 0.76 KDM4E (0.50) KDM4EPKMALDH1A1HPGDHSD17B10
SCHEMBL30983307 0.73 ALDH1A1 (0.47) KDM4EPKMALDH1A1HPGDHSD17B10
SCHEMBL3519204 0.72 PLA2G2A (0.45) KDM4EPKMALDH1A1NPC1GABRA1
SCHEMBL2830367 0.71 CNR1 (0.61) ALDH1A1GABRA1GABRG2GABRB3GABRA5
SCHEMBL30712635 0.71 CNR1 (0.61) ALDH1A1GABRA1GABRG2GABRB3GABRA5
SCHEMBL28241571 0.71 GABRA1 (0.50) KDM4EPKMALDH1A1HPGDHSD17B10
SCHEMBL31017215 0.70 LCK (0.46) KDM4EPKMALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9469615-B2 Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators MERCK SHARP & DOHME CORP. (US) 2016-10-18 US disclosed
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME LLC 2013-11-14 US disclosed
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME LLC 2013-11-14 US disclosed
WO-2012087861-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS HRH2, NPY2R, CNKSR1 KDM4E 1506/4885PKM 3333/4885ALDH1A1 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.